Filing Flows › Sarepta Therapeutics (SRPT) › Recalls, complaints & regulation
Sarepta Therapeutics (SRPT): clinical trials
Sarepta Therapeutics (SRPT) beyond its filings: 13 active clinical trials.
Sarepta Therapeutics' latest quarter
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Sarepta Therapeutics have?
13 active studies on ClinicalTrials.gov, 4 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.